We were retained by counsel for an international pharmaceutical company in connection with a proposed Internal Revenue Service transfer-pricing adjustment. We prepared summaries of financial and other quantitative information spanning a 30-year period (entity-level and product-line financial statements). This information was the basis for negotiating stipulated facts, and it supported other accounting and economic experts.

Prepared financial summaries for an international pharmaceutical firm
Prepared financial summaries for an international pharmaceutical firm
Condividere